New peptides are under evaluation as vaccine targets: B-cell lymphoma extra-large protein (Bcl-xl)_42-CAF09b for mHSPC in the NCT03412786 phase I trial; the TENDU vaccine-targeting tetanus-epitope targeting (TET), in the phase I NCT04701021 for relapsing PCa after RP; the RV001V vaccine-targeting RhoC, in the phase II NCT04114825 for patients with biochemical recurrence after curative radiotherapy (RT) or RP; the combination of BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1-NCT03493945, phase I/II) in the mCRPC setting [83]. Here, BCL2L1 is linked to posterior cortical atrophy.